1261397-71-0
Chemical Structure
Lercanidipine-13C,d3 hydrochloride
- CAS No.: 1261397-71-0
- Formula:C3513CH39D3ClN3O6
- Molecular Weight:652.20
IUPAC Name: 3-(1-((3,3-diphenylpropyl)(methyl-13C-d3)amino)-2-methylpropan-2-yl) 5-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride
InChIKey: WMFYOYKPJLRMJI-VOMAOHKISA-N
SMILES: [2H][13C]([2H])([2H])N(CCC(C1=CC=CC=C1)C2=CC=CC=C2)CC(C)(C)OC(C3=C(C)NC(C)=C(C(OC)=O)C3C4=CC([N+]([O-])=O)=CC=C4)=O.Cl
Biological Activity: Lercanidipine-13C,d3 (hydrochloride) is the deuterium and 13C labeled Lercanidipine hydrochloride[1]. Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect[2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lercanidipine-13C,d3 hydrochloride | Lercanidipine-13C,d3 (hydrochloride) is the deuterium and 13C labeled Lercanidipine hydrochloride. Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lercanidipine hydrochloride (Standard) | ≥98% | Lercanidipine (hydrochloride) (Standard) is the analytical standard of Lercanidipine (hydrochloride). This product is intended for research and analytical applications. Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lercanidipine-13C,d3-1 hydrochloride | Lercanidipine-13C,d3-1 (hydrochloride) is deuterium labeled Lercanidipine (hydrochloride). Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lercanidipine-d3 hydrochloride | 98.14% | Lercanidipine-d3 (hydrochloride) is the deuterium labeled Lercanidipine. Lercanidipine is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine has long lasting antihypertensive action and reno-protective effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lercanidipine hydrochloride | 99.93% | Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract, 2006. 60(11): p. 1364-70. [Content Brief]
- [3]. Burnier, M., M. Pruijm, and G. Wuerzner, Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol, 2009. 5(8): p. 981-7. [Content Brief]
- [4]. Grassi G, et, al. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. Oct-Dec 20178(4):155-165. [Content Brief]
